Roth Capital analyst Scott Henry reiterated a Hold rating on NovaBay Pharma (NBY) on November 16 and set a price target of $2. The company’s shares opened today at $1.15.
According to TipRanks.com, Henry is a 3-star analyst with an average return of 2.4% and a 42.6% success rate. Henry covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Intec Pharma Ltd, and Ligand Pharma.
Currently, the analyst consensus on NovaBay Pharma is a Moderate Buy with an average price target of $2.50.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in commercializing and developing products for eye care. Its products include Avenova, NeutroPhase, and CelleRx. The comapny was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
